Cancer Vaccines
From approved HPV vaccines preventing millions of cancers, to personalised mRNA programs and the EU's vaccine accelerator — the complete global landscape.
Off-Label Drug Use — Consult Your Doctor
Information about repurposed drugs describes off-label uses that are not approved by regulatory agencies. This is not a recommendation to take any drug.
Gardasil 9
Merck (MSD)
Availability: Available now — recommended ages 9–45 (US), 9–26 primary schedule
Cervarix
GlaxoSmithKline (GSK)
Availability: Available now — used in many EU national immunisation programs
Hepatitis B Vaccine
Multiple (GSK, Merck, Dynavax)
Availability: Available now — included in standard infant vaccination schedule globally
mRNA-4157 / V940
Moderna + Merck (MSD)
Availability: Potentially 2026–2027 if Phase 3 succeeds; FDA Breakthrough pathway
BNT122 (Autogene Cevumeran)
BioNTech + Genentech (Roche)
Availability: Phase 2 ongoing — potential availability 2027–2028 if trials succeed
BNT111
BioNTech
Availability: Phase 2 — potential availability 2027+ if trials succeed
Russian mRNA Cancer Vaccine
Gamaleya National Research Centre for Epidemiology and Microbiology + N.N. Blokhin National Medical Research Centre of Oncology
Availability: Phase 1 trials now — broader availability 2027+ if efficacy proven
EU Cancer Vaccines Accelerator
European Commission + BioNTech + multiple EU research centres
Availability: Infrastructure being built 2024–2026; vaccine access under clinical trials in EU hospitals now; broader access 2027+
DCVax-L
Northwest Biotherapeutics
Availability: UK: MHRA reviewing; EU: EMA engagement ongoing. US: not yet FDA-approved. Compassionate use in some EU centres.
Provenge (Sipuleucel-T)
Dendreon (now Valeant / Sanofi)
Availability: Available now in the US for eligible prostate cancer patients
BNT116
BioNTech
Availability: Phase 1 — earliest 2028+ if Phase 3 initiated promptly